On June 6, 2013 Patrys reported that it has been granted a New Zealand patent for lead anti-cancer product PAT-LM1 (Press release Patrys, JUN 6, 2013, View Source [SID:1234500544]).
The New Zealand Patent Office has issued a certificate of grant on a key patent in the PAT-LM1 family, PCT/IB2009/007082 entitled "LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same". It offers patent protection through to year 2029.
This is the second jurisdiction in which the PAT-LM1 patent has been granted.
The patent, which is owned by Patrys, claims the use of the antibody PAT-LM1 that binds to its target Nmt55/NONO for the treatment or prevention of metastasis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!